Bio-Thera’s BAT2506 wins a China first, but can it challenge Johnson & Johnson’s Simponi?
Bio-Thera wins China's first golimumab biosimilar approval for BAT2506, opening a new market while pricing and competition remain critical.
Pharma & Biotech